For prophylaxis of spontaneous bacterial peritonitis, should norfloxacin or rifaximin be used?

Rifaximin is Superior to Norfloxacin for Secondary Prophylaxis of SBP

For secondary prophylaxis (preventing recurrent SBP), rifaximin should be used over norfloxacin, as it significantly reduces SBP recurrence and mortality. For primary prophylaxis, either agent is acceptable, though norfloxacin remains the traditional first-line choice when available.

Secondary Prophylaxis (After Prior SBP Episode)

The evidence strongly favors rifaximin for preventing recurrent SBP:

• Rifaximin demonstrates superior efficacy with only 4-7% recurrence rates compared to 14-39% with norfloxacin 1, 2. This represents a clinically meaningful 70-86% reduction in odds of recurrent SBP 1.

• Mortality benefit: Rifaximin reduces 6-month mortality (13.7% vs 24.4%) compared to norfloxacin, with notably fewer encephalopathy-related deaths 2.

• Better safety profile: Rifaximin causes significantly fewer adverse events than norfloxacin, improving treatment adherence 1, 2.

• Dual benefit: Rifaximin simultaneously reduces hepatic encephalopathy episodes (23% vs 52%), providing additional quality-of-life improvement 1.

The 2021 AASLD guidelines acknowledge this emerging evidence, citing a single-center trial showing rifaximin's lower 6-month SBP recurrence (4% vs 14%) 3. While guidelines still list norfloxacin as traditional first-line, the most recent high-quality RCT data from 2022 1 and systematic reviews 4, 5 consistently demonstrate rifaximin's superiority for secondary prophylaxis.

Dosing for secondary prophylaxis: Rifaximin 550 mg twice daily 1, 2

Primary Prophylaxis (No Prior SBP)

For patients at high risk (ascitic protein <1.5 g/dL, Child-Pugh ≥9, bilirubin ≥3 mg/dL, or renal impairment):

• Both agents show comparable efficacy for primary prophylaxis, with no significant difference in SBP occurrence (14% vs 24%, p=0.5) 1.

• Norfloxacin remains guideline-recommended as first-line when available (400 mg daily) 3, 6. However, norfloxacin was withdrawn from the US market in 2014.

• Acceptable alternatives include:

  • Ciprofloxacin 500 mg daily (though direct evidence is limited) 3, 6
  • Trimethoprim-sulfamethoxazole 800/160 mg daily 6
  • Rifaximin 550 mg twice daily (based on extrapolation from secondary prophylaxis data)

Critical Caveats

Quinolone resistance concerns: The effectiveness of norfloxacin and ciprofloxacin is compromised in patients colonized with multidrug-resistant organisms (MDRO) or in settings with high quinolone resistance 3. This increasingly favors rifaximin, which has broader spectrum coverage and doesn't promote cross-resistance with other antibiotic classes 7.

Special circumstance - GI bleeding: For cirrhotic patients with acute upper GI hemorrhage, use IV ceftriaxone (not oral prophylaxis) until bleeding resolves, as this reduces infections and improves survival 3, 6.

Cost consideration: Rifaximin is significantly more expensive than quinolones, which may limit access despite superior efficacy.

Practical Algorithm

1. Patient with prior SBP episode → Rifaximin 550 mg twice daily
2. High-risk patient without prior SBP:
   • If norfloxacin available → Norfloxacin 400 mg daily
   • If norfloxacin unavailable → Ciprofloxacin 500 mg daily OR rifaximin 550 mg twice daily
   • Consider local resistance patterns
3. Active GI bleeding with ascites → IV ceftriaxone (not oral prophylaxis)

The shift toward rifaximin for secondary prophylaxis represents an evidence-based evolution beyond traditional guidelines, driven by superior outcomes in the most recent trials and the growing problem of quinolone resistance 1, 4, 5, 2.